Episode 7 – Cell line development with Dr Natasa Skoko, ICGEB & Dr Hugh Graham, MacroGenics
Tune in to this podcast to hear industry experts discuss cell line monoclonality and the emerging methods that can support clonal origin assurance.
List view / Grid view
Tune in to this podcast to hear industry experts discuss cell line monoclonality and the emerging methods that can support clonal origin assurance.
Janssen's monoclonal antibody CR9114, for the potential treatment of influenza, has been exclusively licensed by Leyden Labs for development and commercialisation.
12 January 2022 | By Thermo Fisher Scientific
Explore new methods and software enhancements to support your bioanalytical workflows by watching this on-demand webinar.
Altasciences has announced its acquisition of Sinclair Research, a pre-clinical CRO, to expand its services across the US.
In this article, Dmytro Spilka explores three promising biotechs that have seen growth in the last year and why they may continue to garner interest.
In this podcast, join Tyler Pascoe and Matt Gruver from Thermo Fisher Scientific as they explore the new Watson LIMS software.
The UK International Coronavirus Network (UK-ICN) aims to enhance knowledge of the virus family to prepare responses for future outbreaks.
Sanofi has completed the acquisition of mRNA therapeutics company Translate Bio for a total of approximately $3.2 billion.
Dr Robert Hewitt explores why a shift is required in the way that biosamples are sourced by the drug discovery industry, including smaller biotech companies.
Dr Robert Hewitt explains why the need of biospecimen brokers to protect their commercially-sensitive information can result in significant issues for industry end-users and the results of their research.
A National Science and Technology Council and Office for Science and Technology Strategy will be established to aid the UK's scientific industry.
The WHO and Swiss Confederation are set to launch a BioHub Facility, intended to facilitate the sharing of pathogens globally.
Dmytro Spilka explains why UK biotech companies are receiving increasing levels of investment and why this trend is likely to continue.
The UK Government will invest £29.3 million to test the effectiveness of COVID-19 vaccines against variants in 3,000 blood samples a week.
A summit will be held between the UK and CEPI to raise funds for vaccine research and development in a bid to avert future pandemics.